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Background-—Understanding the relative risk of cardiovascular versus noncardiovascular death is important for designing clinical
trials. These risks may differ depending on patient age, sex, and type of acute coronary syndrome (ACS).
Methods and Results-—IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efﬁcacy International Trial) was a randomized
controlled trial of simvastatin plus either ezetimibe or placebo following stabilized ACS. Cause of death was adjudicated by an
independent committee. We compared the cumulative incidence of cardiovascular and noncardiovascular death for patients with
unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI) and ST-segment elevation myocardial infarction
(STEMI), in those <65 and ≥65 years old, and males and females, over 7 years of follow-up. Of 18 131 patients, the presenting
event was STEMI for 5190 (29%) and UA/NSTEMI for 12 941 (71%); 10 173 (56%) patients were <65 years old and 7971 (44%)
were ≥65 years old at presentation. UA/NSTEMI patients were older than STEMI patients, with more cardiovascular and
noncardiovascular risk factors. In STEMI patients, the cumulative incidence of cardiovascular death was higher for  4 years
following the index event, after which noncardiovascular death predominated. In UA/NSTEMI patients, the cumulative incidence of
cardiovascular death remained higher than noncardiovascular death over the full follow-up period. Patients ≥65 years old and
<65 years old had a higher incidence of cardiovascular death than noncardiovascular death over the entirety of follow-up. Female
patients had a higher incidence of cardiovascular death than noncardiovascular death for  6 years following the index event;
male patients had a higher incidence of cardiovascular death than noncardiovascular death over the entirety of follow-up.
Conclusions-—Among post-ACS patients enrolled in a long-term clinical trial, the relative incidence of cardiovascular and
noncardiovascular death differed based on type of ACS presentation and sex, but not age. These ﬁndings further delineate long-
term prognosis after ACS and should inform the design of future cardiovascular outcomes trials. ( J Am Heart Assoc. 2017;6:
e005840. DOI: 10.1161/JAHA.117.005840.)
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P atients with unstable angina (UA) and non-ST-segmentelevation myocardial infarction (NSTEMI) differ from
those with ST-segment elevation myocardial infarction
(STEMI) in important ways; as a group, they are older and
more likely to have both cardiovascular and other comorbidi-
ties, including diabetes mellitus, chronic lung disease, and
chronic kidney disease.1–5 Epidemiologic studies and clinical
trials have mostly demonstrated that all-cause mortality is
greater for patients with STEMI than for those with UA/
NSTEMI over the ﬁrst 2 to 3 months after the event, but over
long-term follow-up, all-cause mortality is higher for patients
with UA/NSTEMI compared with STEMI and for older patients
compared with younger patients.6–16 However, these studies
were unable to reliably capture cause of death and, as such,
are unable to determine the contributions of cardiovascular
and noncardiovascular mortality to overall mortality in post–
acute coronary syndrome (ACS) patients.
The relative incidence of cardiovascular and noncardiovas-
cular death is of particular interest in the design and
interpretation of cardiovascular clinical trials. Failure to
account for the competing risk of noncardiovascular death
can lead to overestimates of event rates observed, and
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noncardiovascular death rates affect sample size as patients
are effectively “censored” at the time of death.17,18 The
relative likelihood of cardiovascular versus noncardiovascular
death after initial presentation with ACS is likely to change
over time and to differ among patients who present with
STEMI and UA/NSTEMI, given differences in baseline charac-
teristics, but this has not been well deﬁned over a prolonged
follow-up period. Further delineation of the long-term fre-
quencies of cardiovascular versus noncardiovascular death
following ACS may inform the design and conduct of future
cardiovascular outcomes trials that commonly incorporate
cardiovascular death into the composite primary outcome and
may help patients and physicians prioritize multiple compet-
ing comorbidities.
The strict adjudication of end points and long duration of
follow-up of contemporary post-ACS patients in the IMPROVE-
IT (Improved Reduction of Outcomes: Vytorin Efﬁcacy Inter-
national Trial) allow for an in-depth exploration of the relative
incidence of cardiovascular and noncardiovascular mortality
in a large cohort of patients with ACS. Speciﬁcally, the goals
of this analysis were to (1) compare the cumulative incidence
of cardiovascular and noncardiovascular death over time in
patients after ACS, and (2) determine whether the relative
contributions of cardiovascular and noncardiovascular mor-
tality varied by presenting diagnosis or patient age.
Methods
The IMPROVE-IT trial design and primary results have been
previously published.19–21 Brieﬂy, IMPROVE-IT was a random-
ized, double-blind, placebo-controlled clinical trial testing the
efﬁcacy and safety of ezetimibe compared with placebo on a
background of simvastatin therapy for the prevention of
cardiovascular events in patients stabilized after hospitaliza-
tion for ACS. Patients were enrolled within 10 days of
hospitalization for ACS, and received simvastatin 40 mg daily
with either ezetimibe or matching placebo. All patients with
acute MI ≥50 years of age; patients with anterior STEMI of
any age; and patients with UA who were ≥50 years old and
had either diabetes mellitus, prior myocardial infarction (MI), a
history of peripheral arterial disease or cerebrovascular
disease, coronary artery bypass grafting within at least
3 years, or known multivessel coronary artery disease were
eligible for inclusion. All patients were required to be
hospitalized with symptoms of acute cardiac ischemia. Key
exclusion criteria included planned coronary artery bypass
grafting surgery, creatinine clearance <30 mL/min, active
liver disease, or ongoing treatment with statin therapy with
greater potency than simvastatin 40 mg daily.
The trial was designed so that the minimum follow-up for
each patient was 30 months; because of prolonged enroll-
ment, the median follow-up was 6 years. The trial began
enrolling patients on October 26, 2005; because of high
enrollment of patients with STEMI in the ﬁrst phase of the
trial, and concern that the lower long-term risk of these
patients would require lengthening of follow-up, enrollment of
these patients was phased out beginning in September 2007
and was nearly complete by April 2008.21 Total enrollment
was completed on July 8, 2010. Though 42% of patients
discontinued the study drug by 6 years, an average of 7% per
year, only 653 patients (3.5%) had unknown vital status at the
conclusion of the trial. This analysis includes all randomized
patients except those with missing MI type (n=13).
Outcomes and Key Covariates
The co-primary outcomes for this analysis were cardiovascular
and noncardiovascular death. Cardiovascular death was
classiﬁed as death caused by coronary heart disease (fatal
MI, sudden death, nonsudden cardiac death, unwitnessed
death, or procedural death), other atherosclerotic disease
(cerebrovascular disease and other), and other nonatheroscle-
rotic cardiovascular disease. Noncardiovascular death was
Clinical Perspective
What Is New?
• This analysis of IMPROVE-IT (Improved Reduction of
Outcomes: Vytorin Efﬁcacy International Trial) demon-
strated that the relative incidence of cardiovascular and
noncardiovascular death differed based on type of acute
coronary syndrome presentation, but not age.
• In patients with ST-segment elevation myocardial infarction,
the cumulative incidence of cardiovascular death was higher
for 4 years following the index event, after which noncar-
diovascular death predominated; however, patients with
non-ST-segment elevation myocardial infarction or unstable
angina had a higher incidence of cardiovascular death over
the full follow-up period.
• Patients ≥65 years old and <65 years old had a higher
incidence of cardiovascular death than noncardiovascular
death over the entirety of follow-up.
What Are the Clinical Implications?
• Patients with unstable angina or non-ST-segment elevation
myocardial infarction remain at higher risk for cardiovascu-
lar death than noncardiovascular death over long-term
follow-up, and their comorbidities should be targeted
appropriately.
• The long-term incidence of cardiovascular death following
admission for unstable angina or non-ST-segment elevation
myocardial infarction remains high, despite advancements
in pharmacotherapy and invasive management.
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classiﬁed as death caused by diabetes mellitus, malignancy,
renal disease, accident, suicide, and other. Clinical end points,
including cause of death, were adjudicated using standardized
deﬁnitions by a clinical events committee blinded to treat-
ment assignment.
STEMI was deﬁned as symptoms of cardiac ischemia,
persistent ST-segment elevation ≥0.1 mV in at least 2
contiguous ECG leads, and elevation in troponin I, troponin
T, or creatine kinase MB fraction above the upper limit of
normal. NSTEMI was deﬁned as symptoms of cardiac
ischemia plus elevation in troponin I, troponin T, or creatine
kinase MB fraction above the upper limit of normal without
persistent ST-segment elevation. Any other patient meeting
inclusion criteria for the study was diagnosed with UA.
Statistical Analysis
Baseline characteristics stratiﬁed by diagnosis (STEMI and
UA/NSTEMI), age (<65 and ≥65 years old), and sex (male and
female) were reported as frequencies with percentages for
categorical variables and as medians (25th, 75th percentiles)
for continuous variables. Categorical variables were compared
using v2 tests, and continuous variables were compared using
analysis of variance; where distributional assumptions were
violated, we used Fisher exact and Kruskal–Wallis tests,
respectively.
We evaluated the cumulative incidence of cardiovascular and
noncardiovascular death over 7 years of follow-up by present-
ing diagnosis (UA/NSTEMI versus STEMI), age (<65 and
≥65 years old), and sex (female versusmale); we also evaluated
the cumulative incidence of noncardiovascular death and the
trial’s primary end point (cardiovascular death, nonfatal MI,
nonfatal stroke, UA requiring hospital admission, or coronary
revascularization occurring at least 30 days after randomiza-
tion) by presenting diagnosis and age. Since these results were
similar for patients randomized to simvastatin and those
randomized to simvastatin plus ezetimibe, pooled data are
presented. Scaled Schoenfeld residuals were used to evaluate
the proportional hazards assumption for STEMI versus UA/
NSTEMI and for age <65 versus ≥65 years old for the outcomes
of cardiovascular and noncardiovascular death over the 7-year
follow-up. Because proportional hazards were not met for the
comparison of cardiovascular death in patients with STEMI
versus UA/NSTEMI, we produced a curve depicting the
estimated hazard ratio of cardiovascular death for patients with
STEMI versus UA/NSTEMI at any given point over the follow-up
interval using the methods described by Lunn andMcNeil.22 We
also tested whether hazard ratios for STEMI versus UA/NSTEMI
and age <65 versus ≥65 years old were different for cardio-
vascular as compared with noncardiovascular death.22
Since the trial stopped enrollment of patients with STEMI
earlier than those with UA/NSTEMI, median duration of
follow-up was different for patients with STEMI compared with
those with UA/NSTEMI. Therefore, as a sensitivity analysis,
we repeated the above analyses including only patients
enrolled from October 26, 2005 through April 1, 2008, the
time period when the trial enrolled both STEMI and UA/
NSTEMI patients.
To account for the fact that the trial inclusion criteria for
patients with UA enriched for patients with more severe
vascular disease, we performed a second sensitivity analysis
that attempted to minimize the effect of the trial inclusion
criteria. For this analysis, we included only patients ≥50 years
old with elevated cardiac biomarkers; in effect, this analysis
compared patients ≥50 years old with STEMI to those with
NSTEMI, independent of enrichment factors.
All participants in IMPROVE-IT provided written informed
consent to participate. The investigators had full access to all
of the data. The Duke Clinical Research Institute performed all
analyses using SAS software, version 9.3.
Results
Baseline Clinical Characteristics
Of 18 144 patients enrolled in IMPROVE-IT, 18 131 had data
for ACS type, and all had data for age. The qualifying ACS
event was STEMI for 5190 patients (28.6%), and UA/NSTEMI
for 12 941 (71.4%), of whom 8555 had NSTEMI and 4386
had UA. Compared with patients with STEMI, patients with
UA/NSTEMI were older and had a higher burden of risk
factors, but were less likely to have undergone percutaneous
coronary intervention (PCI) during hospitalization for their
index event and to have been discharged on guideline-
directed secondary prevention medications (P<0.001 for all
comparisons, Table). Limiting this analysis to the time period
during which both STEMI and UA/NSTEMI were being
enrolled resulted in 5033 presenting with STEMI and 6099
with UA/NSTEMI.
A total of 10 173 patients were <65 years old, and 7971
were ≥65 years old. Compared with younger patients, older
patients more often presented with UA/NSTEMI and had a
higher burden of cardiac risk factors (P<0.001 for all
comparisons). They had less frequently undergone PCI during
hospitalization for their index event, but were taking guideline-
directed medical therapy at a similar rate to younger patients.
Overall, 13 728 patients were male, compared with 4416
patients who were female. Compared with male patients,
female patients were older and had a higher incidence of
hypertension and diabetes mellitus, but a lower incidence of
coronary artery bypass grafting and multivessel coronary
artery disease. Their index event was less likely to be a STEMI,
and they were less likely to have undergone PCI for this index
event than male patients (Table S1).
DOI: 10.1161/JAHA.117.005840 Journal of the American Heart Association 3
Competing Risks of CV and Non-CV Death After ACS Fanaroff et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Ta
bl
e.
Ba
se
lin
e
C
ha
ra
ct
er
is
tic
s
by
AC
S
Ty
pe
an
d
Ag
e
O
ve
ra
ll
(N
=
18
14
4)
AC
S
Ty
pe
Ag
e
ST
EM
I
(N
=
51
90
)
U
A/
N
ST
EM
I
(N
=
12
94
1)
P
Va
lu
e
<
65
Y
(N
=
10
17
3)
≥
65
Y
(N
=
79
71
)
P
Va
lu
e
De
m
og
ra
ph
ic
ch
ar
ac
te
ris
tic
s
Ag
e,
y
63
(5
6,
71
)
60
(5
4,
68
)
64
(5
7,
72
)
<
0.
00
1
57
(5
3,
61
)
72
(6
8,
77
)
<
0.
00
1
M
al
e
se
x
13
72
8
(7
5.
7%
)
41
54
(8
0.
0%
)
95
66
(7
3.
9%
)
<
0.
00
1
81
05
(7
9.
7%
)
56
23
(7
0.
5%
)
<
0.
00
1
W
hi
te
15
20
2
(8
3.
8%
)
44
58
(8
5.
9%
)
10
73
4
(8
2.
9%
)
<
0.
00
1
83
16
(8
1.
8%
)
68
86
(8
6.
4%
)
<
0.
00
1
Bo
dy
m
as
s
in
de
x,
kg
/m
2
28
(2
5,
31
)
27
(2
5,
30
)
28
(2
5,
31
)
<
0.
00
1
28
(2
5,
32
)
27
(2
5,
30
)
<
0.
00
1
Pr
io
r
m
ed
ic
al
hi
st
or
y
Hi
st
or
y
of
hy
pe
rte
ns
io
n
11
13
7
(6
1.
4%
)
24
99
(4
8.
2%
)
86
36
(6
6.
7%
)
<
0.
00
1
56
22
(5
5.
3%
)
55
15
(6
9.
2%
)
<
0.
00
1
Hi
st
or
y
of
di
ab
et
es
m
el
lit
us
49
33
(2
7.
2%
)
10
13
(1
9.
5%
)
39
17
(3
0.
3%
)
<
0.
00
1
25
06
(2
4.
6%
)
24
27
(3
0.
5%
)
<
0.
00
1
Pr
io
r
CH
F
79
0
(4
.4
%
)
70
(1
.3
%
)
72
0
(5
.6
%
)
<
0.
00
1
29
6
(2
.9
%
)
49
4
(6
.2
%
)
<
0.
00
1
Pr
io
r
at
ria
lf
ib
ril
la
tio
n
94
8
(5
.2
%
)
11
9
(2
.3
%
)
82
9
(6
.4
%
)
<
0.
00
1
25
0
(2
.5
%
)
69
8
(8
.8
%
)
<
0.
00
1
Pr
ev
io
us
PA
D
10
05
(5
.5
%
)
15
6
(3
.0
%
)
84
8
(6
.6
%
)
<
0.
00
1
39
1
(3
.8
%
)
61
4
(7
.7
%
)
<
0.
00
1
Pr
io
r
PC
I
35
62
(1
9.
6%
)
45
3
(8
.7
%
)
31
06
(2
4.
0%
)
<
0.
00
1
17
86
(1
7.
6%
)
17
76
(2
2.
3%
)
<
0.
00
1
Pr
io
r
CA
BG
16
84
(9
.3
%
)
96
(1
.9
%
)
15
88
(1
2.
3%
)
<
0.
00
1
61
1
(6
.0
%
)
10
73
(1
3.
5%
)
<
0.
00
1
Hi
st
or
y
of
an
gi
na
74
49
(4
1.
1%
)
10
11
(1
9.
5%
)
64
37
(4
9.
7%
)
<
0.
00
1
36
58
(3
6.
0%
)
37
91
(4
7.
6%
)
<
0.
00
1
Pr
io
r
m
ul
tiv
es
se
lC
AD
27
06
(1
5.
4%
)
21
7
(4
.3
%
)
24
88
(2
0.
0%
)
<
0.
00
1
11
77
(1
1.
9%
)
15
29
(2
0.
0%
)
<
0.
00
1
Pr
ev
io
us
M
I
38
06
(2
1.
0%
)
48
7
(9
.4
%
)
33
16
(2
5.
6%
)
<
0.
00
1
18
64
(1
8.
3%
)
19
42
(2
4.
4%
)
<
0.
00
1
Hi
st
or
y
of
st
ro
ke
68
2
(3
.8
%
)
10
4
(2
.0
%
)
57
8
(4
.5
%
)
<
0.
00
1
25
4
(2
.5
%
)
42
8
(5
.4
%
)
<
0.
00
1
Cu
rr
en
t
sm
ok
er
59
78
(3
3.
0%
)
23
38
(4
5.
1%
)
12
93
9
(2
8.
1%
)
<
0.
00
1
46
14
(4
5.
4%
)
13
64
(1
7.
1%
)
<
0.
00
1
De
ta
ils
of
qu
al
ify
in
g
ev
en
t
ST
EM
I
51
90
(2
8.
6%
)
51
90
(1
00
.0
%
)
..
.
..
.
34
32
(3
3.
8%
)
17
58
(2
2.
1%
)
<
0.
00
1
NS
TE
M
I
85
55
(4
7.
2)
..
.
85
55
(6
6.
1%
)
..
.
45
16
(4
4.
4%
)
40
39
(5
0.
7%
)
<
0.
00
1
UA
43
86
(2
4.
2%
)
..
.
43
86
(3
3.
9%
)
..
.
22
17
(2
1.
8%
)
21
69
(2
7.
2%
)
<
0.
00
1
Ki
lli
p
cl
as
s
<
0.
00
1
1
13
07
7
(7
2.
3%
)
37
37
(7
2.
0%
)
93
38
(7
2.
4%
)
74
34
(7
3.
3%
)
56
43
(7
1.
0%
)
<
0.
00
1
2
11
14
(6
.2
%
)
34
8
(6
.7
%
)
76
6
(5
.9
%
)
49
4
(4
.9
%
)
62
0
(7
.8
%
)
3
30
1
(1
.7
%
)
71
(1
.4
%
)
23
0
(1
.8
%
)
13
2
(1
.3
%
)
16
9
(2
.1
%
)
4
12
6
(0
.4
%
)
62
(1
.2
%
)
64
(0
.5
%
)
67
(0
.7
%
)
59
(0
.7
%
)
Un
kn
ow
n
34
74
(1
9.
2%
97
2
(1
8.
7%
)
25
01
(1
9.
4%
)
20
14
(1
9.
9%
)
14
60
(1
8.
4%
)
Cr
ea
tin
in
e
cl
ea
ra
nc
e
85
(6
6,
10
7)
88
(6
9,
11
0)
83
(6
4,
10
6)
<
0.
00
1
99
(8
1,
12
0)
68
(5
5,
84
)
<
0.
00
1
C
on
tin
ue
d
DOI: 10.1161/JAHA.117.005840 Journal of the American Heart Association 4
Competing Risks of CV and Non-CV Death After ACS Fanaroff et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Cumulative Incidence of Cardiovascular Versus
Noncardiovascular Death by ACS Type
Among patients with UA/NSTEMI, 842 patients (7-year
cumulative incidence 7.7%, 95% conﬁdence interval [CI],
7.2–8.3%) died of cardiovascular causes over the 7-year
follow-up and 730 (7.0%, 95% CI, 6.5–7.5%) died of
noncardiovascular causes. For patients with STEMI, 232
(4.4%, 95% CI, 3.9–5.0%) died of cardiovascular causes and
275 (5.2%, 95% CI, 4.6–5.8%) died of noncardiovascular
causes. The majority of cardiovascular deaths in both
groups were caused by coronary heart disease; speciﬁc
causes of death can be found in Table S2. Noncardiovas-
cular death was most often caused by malignancy in both
groups of patients.
For patients with UA/NSTEMI, the cumulative incidence
of cardiovascular death remained higher than noncardiovas-
cular death over the entirety of the 7-year follow-up;
however, for patients with STEMI, noncardiovascular deaths
outnumbered cardiovascular deaths after  4 years of
follow-up (Figure 1). Patients with STEMI had a greater
hazard of cardiovascular death compared with patients with
UA/NSTEMI for 1 month, after which patients with UA/
NSTEMI had a greater hazard of cardiovascular death
(Figure 2). Patients with STEMI had a smaller risk of
noncardiovascular death than patients with UA/NSTEMI
throughout the entirety of follow-up (hazard ratio 0.73, 95%
CI, 0.63–0.84). Hazard ratios for patients with STEMI
compared with UA/NSTEMI were signiﬁcantly different for
cardiovascular and noncardiovascular death over 7 years of
follow-up (P=0.02). For both STEMI and UA/NSTEMI
patients, the cumulative incidence of the primary composite
outcome was greater than that of noncardiovascular death
alone over the entirety of follow-up (Figure S1).
In a sensitivity analysis performed to account for the fact
that IMPROVE-IT’s inclusion criteria limited enrollment of
patients with UA to those with more severe atherosclerotic
disease or diabetes mellitus, we repeated the above
analyses for patients ≥50 years old with either STEMI or
NSTEMI as their qualifying diagnosis. Patients with these
qualifying diagnoses were included in the trial regardless of
the presence or absence of other risk factors. Overall, the
results were similar to the primary analysis; patients with
NSTEMI had a higher cumulative incidence of cardiovascular
death than noncardiovascular death over the entirety of
follow-up, whereas noncardiovascular deaths predominated
in patients with STEMI after the ﬁrst 4 years of follow-up
(Figure S2). Similarly, patients with STEMI were more likely
to die of cardiovascular causes over the ﬁrst month of
follow-up, after which point patients with NSTEMI were more
likely to die of cardiovascular causes, and patients with
NSTEMI were more likely than patients with STEMI to die ofTa
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noncardiovascular causes for the duration of follow-up
(Figure S3).
In a second sensitivity analysis that accounted for the
different lengths of follow-up for STEMI and UA/NSTEMI
patients, we limited our population to patients enrolled while
the trial was enrolling both categories of patients, with
ﬁndings again similar to the primary analysis (Figure S4).
Cumulative Incidence of Cardiovascular Versus
Noncardiovascular Death By Age and Sex
Among patients <65 years old, 350 patients (7-year cumula-
tive incidence 3.8%, 95% CI, 3.4–4.3%) died of cardiovascular
causes over 7 years of follow-up, compared with 321 (3.5%,
95% CI, 3.1–4.0%) who died of noncardiovascular causes. In
patients ≥65 years old, 725 patients (10.3%, 95% CI, 9.5–
11.0%) died of cardiovascular causes over 7-year follow-up,
and 685 (10.0%, 95% CI, 9.3–10.8%) died of noncardiovascu-
lar causes. In both groups, the most common cause of
cardiovascular death was death attributable to coronary heart
disease and the most common cause of noncardiovascular
death was malignancy (Table S1). Both patients <65 and
those ≥65 years old had a higher cumulative incidence of
cardiovascular compared with noncardiovascular death over
the entirety of follow-up (Figure 3). Compared with patients
<65 years old, patients ≥65 years old were roughly 3-fold
more likely than patients <65 years old to die because of
either cardiovascular (hazard ratio 2.89; 95% CI, 2.54–3.28) or
noncardiovascular causes (hazard ratio 3.06; 95% CI, 2.68–
3.50) over the 7-year follow-up. Hazard ratios for patients <65
compared with those ≥65 years old were not signiﬁcantly
different between cardiovascular and noncardiovascular death
(P=0.53). For patients <65 years old and those ≥65 years old,
the cumulative incidence of the primary composite outcome
was greater than that of noncardiovascular death alone over
the entirety of follow-up (Figure S5).
Among male patients, 816 died of cardiovascular causes
over 7 years of follow-up (7-year cumulative incidence 6.6%,
95% CI, 6.2–7.1%), compared with 759 (6.3%, 95% CI, 5.8–
6.7%) who died of noncardiovascular causes. Among female
Figure 1. Cumulative incidence of cardiovascular and noncardiovascular death for patients with (A) STEMI
and (B) UA/NSTEMI. Seven-year Kaplan–Meier mortality rates: cardiovascular death: STEMI, 4.5%; UA/
NSTEMI, 6.5%; noncardiovascular death: STEMI, 5.3%; UA/NSTEMI, 5.6%. CV indicates cardiovascular;
NSTEMI, non-ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial
infarction; UA, unstable angina.
Figure 2. Hazard ratio (HR) for death over time for STEMI
compared with UA/NSTEMI. HR curves are truncated at
6 months, but HRs for cardiovascular and noncardiovascular
death remained constant through the end of follow-up. Solid lines
represent HR curves; dashed lines represent 95% conﬁdence
limits with conﬁdence interval denoted by shading. CV indicates
cardiovascular; NSTEMI, non-ST-segment elevation myocardial
infarction; STEMI, ST-segment elevation myocardial infarction; UA,
unstable angina.
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patients, 259 (6.6%, 95% CI, 5.8–7.4%) died of cardiovascular
causes over the 7-year follow-up and 247 (6.5%, 95% CI, 5.7–
7.4%) died of noncardiovascular causes. In both groups, the
most common cause of cardiovascular death was death
caused by coronary heart disease, and the most common
speciﬁc cause of noncardiovascular death was malignancy
(Table S2). Male patients had a higher cumulative incidence of
cardiovascular death than noncardiovascular death over the
entirety of follow-up; whereas among female patients, the
cumulative incidence of noncardiovascular death equaled that
of cardiovascular death after 6 years of follow-up (Figure S6).
Discussion
In this analysis of IMPROVE-IT, we demonstrate that, among
patients stabilized after ACS, the relative contributions of
cardiovascular and noncardiovascular death to overall mortality
over long-term follow-up differ by type of presenting diagnosis.
Although older patients were 3-fold more likely than younger
patients to die of either cardiovascular or noncardiovascular
causes over the duration of follow-up, the relative contributions
of cardiovascular and noncardiovascular death were not
affected by age. Similarly, both men and women were more
likely to die of cardiovascular causes over the entirety of follow-
up. By contrast, patients with UA/NSTEMI were more likely to
die of cardiovascular versus noncardiovascular causes for the
entirety of follow-up; however, in patients with STEMI, cardio-
vascular death was more common than noncardiovascular
death only for  4 years, after which noncardiovascular death
predominated. The sensitivity analyses suggest that the larger
contribution of cardiovascular death to mortality in patients
with NSTEMI was not because of trial inclusion parameters or
differential follow-up length speciﬁc to IMPROVE-IT, but rather
because of patient factors.
In IMPROVE-IT, patients presenting with STEMI had higher
mortality than those presenting with UA/NSTEMI for the ﬁrst
month, after which mortality rates in those with UA/NSTEMI
were higher. This crossover is similar to what has been shown
elsewhere, where patients with STEMI have higher in-hospital
and short-term all-cause mortality rates than those with UA/
NSTEMI; but over longer-term follow-up, cumulative mortality
for patients with UA/NSTEMI catches up with or surpasses
that of STEMI patients.8,9,13,23,24 Our ﬁnding of that crossover
occurring within 1 month is earlier than has been shown in
other studies, and likely reﬂects the enrollment criteria of
stabilization required before randomization. Long-term higher
cardiovascular and noncardiovascular mortality among UA/
NSTEMI patients has been attributed to a higher baseline
prevalence of multiple comorbidities, including multivessel
coronary artery disease, heart failure, diabetes mellitus,
chronic kidney disease, and chronic lung disease, a ﬁnding
we also demonstrated in patients in IMPROVE-IT.1,2,5,7,9,10
Thus, it is important for clinicians and patients to understand
that patients with UA/NSTEMI remain at higher risk for
cardiovascular than noncardiovascular death over long-term
follow-up, and that care of their multiple comorbidities should
be targeted appropriately. Moreover, despite numerous
pharmacologic, interventional, and surgical improvements,
long-term cardiovascular mortality following NSTEMI remains
high.
In IMPROVE-IT, patients with UA/NSTEMI had a higher
cumulative incidence of cardiovascular death than noncardio-
vascular death throughout the follow-up period. By contrast,
for patients with STEMI, the cumulative incidence of cardio-
vascular death was higher than noncardiovascular death for
the ﬁrst 4 years, after which noncardiovascular death
predominated. These ﬁndings are similar to those seen in
an analysis of a registry of Japanese patients undergoing
Figure 3. Cumulative incidence of cardiovascular and noncardiovascular death for patients (A) <65 years
old and (B) ≥65 years old. Seven-year Kaplan–Meier mortality rates: cardiovascular death: <65 years old,
3.4%; ≥65, 9.1%; noncardiovascular death: <65, 3.2%; ≥65, 8.6%). CV indicates cardiovascular.
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primary PCI: when patients with death within 6 months after
PCI were excluded, the cumulative incidence of noncardio-
vascular death was greater than that of cardiovascular death
after 2 to 3 years.25 We demonstrated, through our sensitivity
analyses, that the likeliest explanation for these ﬁndings is
that UA/NSTEMI patients’ cardiovascular comorbidities were
more extensive than those of STEMI patients, and continued
to outweigh noncardiovascular comorbidities throughout
follow-up. The sensitivity analysis limited to patients enrolled
while the trial was enrolling both STEMI and UA/NSTEMI
patients was similar to the primary analysis, suggesting that
differential follow-up does not explain our ﬁndings. The
second sensitivity analysis, limited to patients with positive
cardiac biomarkers, controlled for differences in enrollment
criteria between the STEMI and UA/NSTEMI cohorts of
IMPROVE-IT. IMPROVE-IT limited enrollment of patients with
UA/NSTEMI to those with positive cardiac biomarkers (ie,
patients with NSTEMI) or UA with comorbidities that increase
the likelihood of cardiovascular death.26–28 This analysis was
also similar to the primary analysis, suggesting that IMPROVE-
IT’s differential inclusion criteria did not drive our results.
Thus, the relative impact of noncardiovascular death on event
rates will vary both over time and by presenting diagnosis.
Although death rates were higher in older adults, there was no
difference in the relative incidence of cardiovascular com-
pared with noncardiovascular death in older and younger
adults.
Understanding the relative incidence of cardiovascular and
noncardiovascular death has important implications for clin-
ical trial design. Most clinical trials in cardiovascular disease
utilize Kaplan–Meier or Cox proportional hazards analyses to
compare rates of composite end points, usually including
cardiovascular mortality, between treatment arms.20,29,30
Noncardiovascular death acts as a competing risk, as patients
who die are unable to subsequently experience a cardiovas-
cular end point. Assuming that neither treatment arm has an
effect on noncardiovascular mortality, failure to account for
noncardiovascular death is unlikely to affect the point
estimate for the treatment effect.31,32 However, whether
using traditional or a competing events framework, noncar-
diovascular deaths will reduce statistical power to identify a
difference between groups as patients experiencing noncar-
diovascular death are censored at the time of death. This
requires the recruitment of more patients or longer-term
follow-up to accrue sufﬁcient events. For trials that use all-
cause mortality as an end point, a treatment targeted to a
cardiovascular pathway should have no effect on noncardio-
vascular death, and noncardiovascular deaths will not add to
the power to identify a difference between groups. Indeed, if 1
group has a lower proportion of cardiovascular deaths than a
comparator because of treatment efﬁcacy, but a higher
proportion of noncardiovascular deaths by random chance,
then using all-cause mortality as a component of the primary
end point may obscure the true treatment effect. Though we
found that the cumulative incidence of composite primary
outcome events remains substantially higher than that of
noncardiovascular death over the entirety of follow-up in all
groups studied, our ﬁndings suggest that following patients
with STEMI past 4 years may yield diminishing returns as
noncardiovascular deaths accrue faster than cardiovascular
deaths, but that patients with UA/NSTEMI will continue to
accrue cardiovascular deaths faster than noncardiovascular
deaths for at least 7 years after their initial event. By contrast,
neither sex nor older age appeared to have any effect on the
relative incidence of cardiovascular compared with noncar-
diovascular death, though patients >65 years old had a 3-fold
higher incidence of both cardiovascular and noncardiovascu-
lar mortality. Any statistical power lost from noncardiovascu-
lar death among patients >65 years old should be offset by a
higher rate of cardiovascular death in this population.
Limitations
In sensitivity analysis, we did not ﬁnd that our results were
impacted by trial inclusion parameters or differential follow-up
length in different subgroups. However, patient populations
that enroll in clinical trials are different from those that do
not,33,34 and our ﬁndings regarding the relative risk of
cardiovascular and noncardiovascular death for patients
enrolled in IMPROVE-IT may not apply more generally to the
broader population with ACS. Furthermore, IMPROVE-IT
enrolled patients following discharge after an index ACS
presentation, and these stabilized patients are likely to differ
substantially from the full population of patients admitted to
the hospital with ACS. However, our results were broadly
consistent with a similar analysis performed in a registry
population, but mortality rates were lower.25 Regardless, our
ﬁndings are applicable to the population of stabilized ACS
patients likely to be enrolled in clinical trials, and thus provide
important information to guide design of future clinical trials.
Conclusion
In this analysis of IMPROVE-IT, we demonstrate that, among
patients stabilized after ACS, the relative contribution of
cardiovascular and noncardiovascular death to overall mor-
tality varies depending on type of ACS presentation and
duration elapsed since the index event, but not depending on
age at presentation. Noncardiovascular death competes with
cardiovascular outcomes, effectively reducing sample size.
Efﬁcient design of long-term cardiovascular outcome trials
requires that sample size and power calculations include
careful consideration of the competing risks of cardiovascular
and noncardiovascular deaths when determining the desired
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proportions of patients with STEMI versus UA/NSTEMI. Our
analysis speciﬁcally informs these considerations, and thus
should be valuable and informative for future post-ACS clinical
trial design.
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Table S1. Baseline characteristics by sex 
 
Overall 
(N=18,144) 
Sex 
Male 
(N=13,728) 
Female 
(N=4416) 
P value 
Demographic characteristics     
Age, yrs 63 (56, 71) 62 (56, 70) 65 (58, 73) < 0.001 
White 15,202 (83.8%) 11,615 (84.6%) 3587 (81.2%) < 0.001 
Body mass index, kg/m2 28 (25, 31) 28 (25,31) 28 (24, 32) 0.10 
Prior medical history     
History of hypertension 11,137 (61.4%) 8044 (58.6%) 3093 (70.1%) < 0.001 
History of diabetes 4933 (27.2%) 3526 (25.7%) 1407 (31.9%) < 0.001 
Prior CHF 790 (4.4%) 552 (4.0%) 238 (5.4%) < 0.001 
Prior atrial fibrillation 948 (5.2%) 700 (5.1%) 248 (5.6%) 0.18 
Previous PAD 1005 (5.5%) 737 (5.4%) 268 (6.1%) 0.08 
Prior PCI 3562 (19.6%) 2830 (20.6%) 732 (16.6%) < 0.001 
Prior CABG  1684 (9.3%) 1385 (10.1%) 299 (6.8%) < 0.001 
History of angina 7449 (41.1%) 5585 (40.7%) 1864 (42.3%) < 0.001 
Prior multivessel CAD 2706 (15.4%) 2168 (16.4%) 538 (12.5%) < 0.001 
Previous MI 3806 (21.0%) 3051 (22.3%) 755 (17.1%) < 0.001 
History of stroke 682 (3.8%) 486 (3.5%) 196 (4.4%) 0.006 
Current smoker 5978 (33.0%) 4688 (34.2%) 1290 (29.2%) < 0.001 
Details of qualifying event      
STEMI 5190 (28.6%) 4154 (30.3%) 1036 (23.5%) < 0.001 
NSTEMI 8555 (47.2) 6419 (46.8%) 2136 (48.4%) 0.06 
UA 4386 (24.2%) 3147 (22.9%) 1239 (28.1%) < 0.001 
Killip class    < 0.001 
1 13,077 (72.3%) 10,004 (73.0%) 3073 (69.9%)  
2 1114 (6.2%) 792 (5.8%) 322 (7.3%)  
3 301 (1.7%) 216 (1.6%) 85 (1.9%)  
4 126 (0.4%) 89 (0.6%) 37 (0.8%)  
Unknown 3474 (19.2% 2597 (19.0%) 877 (20.0%)  
Creatinine clearance 85 (66, 107) 88 (69, 110) 74 (56, 95) < 0.001 
 
 
 
 
 
Overall 
(N=18,144) 
Sex 
Male 
(N=13,728) 
Female 
(N=4416) 
P value 
Treatment for qualifying event     
PCI during index hospitalization 12,641 (69.7%) 9934 (72.4%) 2707 (61.3%) < 0.001 
CABG within 30 days of 
randomization  
167 (0.9%) 141 (1.0%) 26 (0.6%) 0.008 
Concomitant medications at 
randomization  
    
Asprin 17,898 (98.7%) 13,568 (98.9%) 4330 (98.2%) < 0.001 
Beta-blocker 16,672 (91.9%) 12,644 (92.1%) 4028 (91.3%) 0.07 
P2Y12 inhibitor 16,455 (90.8%) 12,605 (91.9%) 3850 (87.3%) < 0.001 
ACE inhibitor 12,743 (70.3%) 9820 (71.6%) 2923 (66.3%) < 0.001 
Nitrates 13,418 (74.0%) 10,119 (73.8%) 3299 (74.8%) 0.18 
 
Continuous data presented as median (25th, 75th percentile); categorical data presented as count 
(percentage).  
STEMI, ST segment elevation myocardial infarction; NSTEMI, non-STEMI; UA, unstable angina; CHF, 
congestive heart failure; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; 
CABG, coronary artery bypass graft; CAD, coronary artery disease; MI, myocardial infarction; ACE, 
angiotensin-converting enzyme. 
  
 
 
 
 
Table S2. Causes of death for patients with STEMI, UA/NSTEMI, < 65 years old, ≥ 65 years old, male, and female 
 
ACS Type Age Sex 
STEMI 
(N=5190) 
UA/NSTEMI 
(N=12,941) 
< 65 years 
(N=10,173) 
≥ 65 years 
(N=7971) 
Male 
(N = 13,728) 
Female  
(N = 4,416) 
CV death       
Coronary heart disease 232 (4.5%) 842 (6.5%) 350 (3.4%) 725 (9.1%) 816 (5.9%) 259 (5.9%) 
Acute MI 195 (3.8%) 705 (5.5%) 311 (3.1%) 590 (7.4%) 691 (5.0%) 210 (4.8%) 
Sudden death 35 (0.7%) 84 (0.7%) 50 (0.5%) 69 (0.9%) 89 (0.7%) 30 (0.7%) 
Non-sudden death 96 (1.9%) 305 (2.4%) 158 (1.6%) 244 (3.1%) 315 (2.3%) 87 (2.0%) 
Unwitnessed death 31 (0.7%) 224 (1.7%) 51 (0.5%) 204 (2.6%) 197 (1.4%) 58 (1.3%) 
Procedural death 29 (0.6%) 66 (0.5%) 39 (0.4%) 56 (0.7%) 67 (0.5%) 28 (0.6%) 
Atherosclerotic vascular disease 4 (0.1%) 26 (0.2%) 13 (0.1%) 17 (0.2%) 23 (0.2%) 7 (0.2%) 
Cerebrovascular disease 30 (0.6%) 104 (0.8%) 29 (0.3%) 105 (1.3%) 97 (0.7%) 37 (0.8%) 
Other atherosclerotic disease 25 (0.5%) 78 (0.6%) 23 (0.2%) 80 (1.0%) 76 (0.6%) 27 (0.6%) 
Other cardiovascular disease 5 (0.1%) 26 (0.2%) 6 (0.1%) 25 (0.3%) 21 (0.2%) 10 (0.2%) 
Non-CV death 7 (0.1%) 33 (0.3%) 10 (0.1%) 30 (0.4%) 28 (0.2%) 12 (0.3%) 
Accidental 275 (5.3%) 730 (5.6%) 321 (3.2%) 685 (8.6%) 759 (5.5%) 247 (5.6%) 
Diabetes 6 (0.1%) 28 (0.2%) 14 (0.1%) 20 (0.3%) 28 (0.2%) 6 (0.1 %) 
Malignancy 0 (0%) 1 (0.01%) 0 (0%) 1 (0.01%) 1 (0.01%) 0 (0%) 
Renal 163 (3.1%) 389 (3.0%) 210 (2.1%) 342 (4.3%) 442 (3.2%) 110 (2.5%) 
Suicide 5 (0.1%) 19 (0.2%) 6 (0.1%) 18 (0.2%) 14 (0.1%) 10 (0.2%) 
Other 2 (0.04%) 7 (0.1%) 5 (0.1%) 4 (0.1%) 8 (0.1%) 1 (0.02%) 
Unknown cause 99 (1.9%) 286 (2.2%) 86 (0.9%) 300 (3.8%) 266 (1.9%) 120 (2.7%) 
 
 
 
 
CV, cardiovascular; MI, myocardial infarction. Sudden death defined as unexpected death in which the time is known, with or without 
preceding angina symptoms. Non-sudden coronary heart disease death defined as death occurring in a patient with cardiovascular 
symptoms and gradual deterioration prior to death. Unwitnessed death defined as unexpected death with unknown time or alternative 
cause of death. Procedural death was adjudicated when a patient died within 7 days or during the same hospitalization as cardiac 
surgery, percutaneous intervention, or angiography. Cerebrovascular death defined as death occurring secondary to stroke, intracranial 
hemorrhage, or peri-cerebrovascular procedure. Other atherosclerotic disease death defined as death secondary to aortic, mesenteric, 
renal, or peripheral vascular disease, or procedures related to these vascular beds. Other cardiovascular disease death included death 
due to endocarditis, valvular heart disease, or endocarditis. Non-cardiovascular causes were not strictly defined; other non-
cardiovascular death required a cause of death to be specified. If cause of death was not known, it was adjudicated as unknown.  
 
 
 
 
Figure S1. Cumulative incidence of the primary composite outcome and non-CV death for 
patients with A) STEMI and B) UA/NSTEMI 
 
Shading around each curve represents the 95% confidence interval  
 
 
 
 
Figure S2. Cumulative incidence of CV and non-CV death for patients > 50 years old with A) 
STEMI and B) NSTEMI  
 
Shading around each curve represents the 95% confidence interval   
 
 
 
 
Figure S3. Hazard ratio for death over time for STEMI compared to NSTEMI among patients > 
50 years old 
 
HR curves are truncated at 6 months, but HRs for CV and non-CV death remained constant 
through the end of follow-up.  
 
 
 
 
Figure S4. Cumulative incidence of CV and non-CV death for patients with A) STEMI and B) 
UA/NSTEMI enrolled before April 1, 2008 
 
Shading around each curve represents the 95% confidence interval   
 
 
 
 
Figure S5. Cumulative incidence of the primary composite outcome and non-CV death for 
patients with A) < 65 years old and B) ≥ 65 years old 
 
Shading around each curve represents the 95% confidence interval   
 
 
 
 
Figure S6. Cumulative incidence of CV and non-CV death for A) male and B) female patients 
 
Shading around each curve represents the 95% confidence interval 
